Welcome to our dedicated page for NextPlat SEC filings (Ticker: NXPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextPlat Corp (NASDAQ: NXPL, NXPLW) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detail on its healthcare, communications and e-commerce activities, as well as its corporate governance and listing status. These SEC filings, including current reports on Form 8-K, offer insight into material events such as leadership changes, compensation arrangements, financial results announcements and communications with the Nasdaq Stock Market about listing requirements.
Recent 8-K filings describe matters such as the appointment of a new Chief Financial Officer, amendments to the Chief Executive Officer’s employment agreement and compensation, and notices from Nasdaq regarding the company’s compliance with the minimum bid price requirement. Other filings reference press releases that announce quarterly financial results and provide operational updates across NextPlat’s healthcare services, satellite-enabled communications and e-commerce development programs.
On this page, users can review NextPlat’s SEC filings to understand how the company reports its business segments, material contracts, and significant corporate actions. Forms such as 10-K annual reports and 10-Q quarterly reports, when available, typically contain segment information, risk factor discussions and management’s analysis of operations. Current reports on Form 8-K document specific events, while other filings may address equity incentive plans, executive compensation and governance matters.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers interpret complex disclosures. Real-time updates from the SEC’s EDGAR system ensure that new NextPlat filings appear promptly, and users can also review Form 4 insider transaction reports when they are filed to see reported purchases, sales or grants of company securities by officers, directors and significant shareholders. This combination of primary filings and AI-generated insights can help investors and researchers analyze NextPlat’s regulatory disclosures more efficiently.
NextPlat Corp reported full-year 2025 revenue of approximately $54.3 million, down 18% from about $66.1 million in 2024, as healthcare prescription volumes declined but e-commerce grew modestly. Healthcare revenue fell to $39.7 million from $52.3 million, driven by fewer prescriptions and lower 340B contract revenue, partly offset by higher reimbursement per script.
e-Commerce revenue increased to $14.6 million from $13.8 million on stronger airtime and hardware sales and favorable foreign exchange. Overall gross margin declined to about 20% from 26%, but total operating expenses were cut roughly in half to $19.9 million from $40.0 million, reflecting cost reductions and the absence of a prior-year impairment loss. Net loss attributable to common stockholders narrowed to approximately $11.7 million, or $0.44 per share, from $13.4 million, or $0.65 per share. The company ended 2025 with about $13.7 million in cash and roughly $15.0 million in working capital.
NextPlat Corp is a Nevada-based global e-commerce and healthcare services company operating two segments: e-Commerce Operations and Healthcare Operations. For the year ended December 31, 2025, approximately 27% of revenue came from e-Commerce and 73% from healthcare.
The e-Commerce segment sells satellite communications equipment and recurring airtime services through three proprietary websites, about 25 third-party storefronts and more than 10,000 product listings, reaching customers in over 165 countries. Amazon marketplaces represented approximately 31% of e-Commerce revenue in 2025.
The healthcare segment operates Progressive Care’s Pharmco pharmacies and ClearMetrX, providing retail and long-term care pharmacy services, 340B contract pharmacy services, data analytics and medication management in Florida and multiple other states. A Five Star EQuIPP performance score in 2025 highlights strong adherence metrics.
The company remains loss-making, with net losses of approximately $10.5 million in 2025 and $22.5 million in 2024 and an accumulated deficit of about $60.1 million as of December 31, 2025. As of March 27, 2026, there were 27,026,215 common shares outstanding, and non-affiliate equity was valued at about $11.2 million as of June 30, 2025.
NextPlat faces significant risks, including reliance on Amazon for e-commerce sales, dependence on McKesson for about 98% of pharmaceutical purchases in 2025, heavy use of the 340B Drug Pricing Program, and extensive healthcare and data privacy regulation. The company has received Nasdaq notices for failing to meet the $1.00 minimum bid price and pursued a 1-for-10 reverse stock split approved on March 27, 2026 to regain compliance and avoid potential delisting.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock to address Nasdaq’s minimum bid price requirement. At 12:01 a.m. Eastern Time on April 6, 2026, every 10 shares will be combined into one share, reducing outstanding common shares from 27,026,215 to approximately 2,702,621, with cash paid for fractional shares. Stockholders approved the reverse split at a special meeting where 15,510,728 shares voted, representing about 57.5% of the 26,976,215 shares outstanding as of March 16, 2026, and the proposals received strong support. The split affects all holders uniformly, keeps authorized share counts unchanged, and proportionately adjusts equity incentive plans and outstanding options and warrants.
NextPlat Corp is calling a virtual special meeting on March 27, 2026 to ask stockholders to approve a reverse stock split and a possible adjournment of the meeting. Holders of 26,976,215 shares outstanding as of March 2, 2026 are entitled to vote.
The board is seeking authority, at its discretion, to combine between five and fifty existing shares into one new share, with an aggregate maximum of 1-for-50, without changing the 50,000,000 authorized common shares or the $0.0001 par value. The stated goal is to lift the share price to regain compliance with Nasdaq’s $1.00 minimum bid requirement and preserve exchange listing and related financing flexibility.
The proxy explains that failure to approve the reverse split and restore the bid price above $1.00 for at least ten consecutive trading days before April 27, 2026 could trigger Nasdaq delisting, reduced liquidity, loss of Form S-3 shelf eligibility and more difficult access to capital. It also details potential risks of volatility, reduced liquidity, more odd-lot holdings and possible declines in market capitalization even if the split is implemented.
NextPlat Corp is asking shareholders to vote at a Special Meeting on April 6, 2026 to approve a proposed reverse stock split combining every 1-for-5 to 1-for-50 shares (exact ratio to be set by the Board) to regain compliance with Nasdaq’s $1.00 minimum bid requirement.
The Record Date for voting is March 2, 2026, and there were 26,976,014 shares outstanding as of March 2, 2026. If approved, the Board may implement the reverse split and file the amendment; the company notes a Nasdaq compliance deadline of April 27, 2026. The proxy also includes a proposal to adjourn the meeting to solicit additional proxies if necessary.
NextPlat Corp entered into a formal Employment Agreement with Amanda L. Ferrio on January 9, 2026, confirming her role as Chief Financial Officer for an initial three-year term, with potential one-year renewals at the CEO’s discretion.
The Agreement provides a base salary of $225,000 per year, a monthly auto allowance of $650, eligibility for annual cash bonuses, and participation in equity incentive plans, along with company-paid health insurance and other standard benefits. If Ms. Ferrio is terminated without cause or resigns for good reason, she is entitled to six months of base salary and up to six months of COBRA premiums, subject to signing a release. The Agreement also includes customary confidentiality, non-competition, and non-solicitation covenants during employment and for specified periods after it ends.
NextPlat Corp director Anthony Armas reported an acquisition of 10,588 shares of NextPlat common stock on December 31, 2025. The shares were acquired at a price of $0.00 per share and are held indirectly through Apollo Two MSO LLC. Following this transaction, Armas is reported as beneficially owning 101,154 shares of NextPlat common stock through this entity, over which he has voting and dispositive power.
NextPlat Corp director Douglas Ellenoff reported an acquisition of company stock. On 12/31/2025, he acquired 21,176 shares of NextPlat common stock at a reported price of $0.00 per share, indicating a grant or award rather than an open-market purchase. Following this transaction, he directly holds 166,176 shares of NextPlat common stock. This filing is a regulatory disclosure of his updated ownership position.
NextPlat Corp has filed a shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units. These securities may be sold from time to time in one or more offerings, with final terms set in separate prospectus supplements, and net proceeds are expected to be used for working capital and general corporate purposes.
The company operates two main businesses: global e-commerce operations focused on satellite-based communications products and platforms, and healthcare operations delivered through Progressive Care, which provides pharmacy, data analytics and healthcare technology services. Recent acquisitions include Outfitter Satellite, Inc. in 2024 to expand U.S. satellite connectivity services and Progressive Care, LLC, now a wholly owned subsidiary. As of December 10, 2025, NextPlat reported a public float of approximately $9.5 million based on 15,074,825 common shares held by non-affiliates at $0.63 per share, and it has a history of net losses and an accumulated deficit, with risk factors highlighting potential stock price volatility and dilution from future equity issuance.
NextPlat Corp filed a current report describing that it has issued a press release announcing its financial results for the quarter ended September 30, 2025. The company notes that this press release is furnished as Exhibit 99.1 to the report and relates to its results of operations and financial condition.
The report clarifies that the information provided under Item 2.02 and in the exhibit is furnished rather than filed, meaning it is not automatically subject to certain liability provisions under U.S. securities laws unless specifically incorporated into other filings. NextPlat’s common stock and warrants continue to trade on The Nasdaq Stock Market under the symbols NXPL and NXPLW, respectively.